Evan Zisholtz
Vice President, Corporate Development Immunai
Evan Zisholtz is Vice President of Corporate Development at Immunai, where he leads strategic partnerships, business development, and transaction activities to support the company’s AI-driven immunology platform. He has experience across biotechnology strategy and corporate development, with a focus on enabling collaborations between technology-driven companies and pharmaceutical partners to advance immunology and drug discovery programs.
Seminars
Thursday 10th September 2026
Which Platform Technologies are Widening the Immunology & Oncology Fields?
2:30 pm
- How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
- How are we are validating new, and assessing novel versus de-risked targets?
- What type of clinical data would lead the field to reassess assumptions on a target?
